January 12, 2017January 13, 2017

Key Ingredient in RegeneRx’s RGN-352 Treatment for MS Wins Australian Patent

News

Australia has granted a patent to RegeneRx Biopharmaceuticals for an active ingredient in a therapy that could benefit multiple sclerosis (MS) patients. The patent is for Thymosin beta ... Read more

August 31, 2016August 31, 2016

RegeneRx to Receive EU Patent for Molecule That May Lead to MS Remyelination Therapy

News

RegeneRx Biopharmaceuticals announced that it has received an Intent to Grant notice from the European Patent Office (EPO) regarding a patent for its proprietary molecule Thymosin beta 4 (Tβ4), ... Read more

Pin It on Pinterest